Literature DB >> 35195774

A review on the effect of gut microbiota on metabolic diseases.

Qiwei Shi1, Lingli Dai2, Qi Zhao1, Xian Zhang3,4.   

Abstract

Human gut microbiota are a huge and complex microbial community, which is recognized to play a significant role in regulating host metabolism. However, the destruction of gut microbiota leads to the pathological response of host, and thus results in a variety of metabolic diseases. This article gives a brief review of research progress on gut microbiota and some main metabolic diseases, including osteoporosis, obesity, type 2 diabetes, non-alcoholic fatty liver, and hypertension, with a specific focus on the effect of gut microbiota on diseases' occurrence and development. In addition, this review article also shows some case studies on the regulation of gut microbiota by new means, such as fecal microbiota transplantation and oral probiotics. Although gut microbiota are considered as a promising novel target for the treatment of metabolic diseases, it is also necessary to encourage further studies to provide more valuable data for guiding the application of gut microbiota on disease therapy in future.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Disease therapy; Gut microbiota; Metabolic diseases; Novel target

Mesh:

Year:  2022        PMID: 35195774     DOI: 10.1007/s00203-022-02802-3

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  51 in total

Review 1.  Type 2 diabetes.

Authors:  Sudesna Chatterjee; Kamlesh Khunti; Melanie J Davies
Journal:  Lancet       Date:  2017-02-10       Impact factor: 79.321

Review 2.  What's new in NAFLD pathogenesis, biomarkers and treatment?

Authors:  Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02       Impact factor: 46.802

Review 3.  Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification.

Authors:  Alastair D Burt; Carolin Lackner; Dina G Tiniakos
Journal:  Semin Liver Dis       Date:  2015-09-17       Impact factor: 6.115

4.  Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model.

Authors:  Robert A Britton; Regina Irwin; Darin Quach; Laura Schaefer; Jing Zhang; Taehyung Lee; Narayanan Parameswaran; Laura R McCabe
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

Review 5.  Triglyceride Metabolism in the Liver.

Authors:  Michele Alves-Bezerra; David E Cohen
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

Review 6.  Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

Authors:  Judith Aron-Wisnewsky; Karine Clément; Max Nieuwdorp
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

7.  Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans.

Authors:  Joshua N Farr; Jennifer L Rowsey; Brittany A Eckhardt; Brianne S Thicke; Daniel G Fraser; Tamar Tchkonia; James L Kirkland; David G Monroe; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2019-06-21       Impact factor: 6.741

Review 8.  Probiotics in non-alcoholic fatty liver disease: which and when.

Authors:  Ludovico Abenavoli; Emidio Scarpellini; Samir Rouabhia; Clara Balsano; Francesco Luzza
Journal:  Ann Hepatol       Date:  2013 May-Jun       Impact factor: 2.400

Review 9.  Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.

Authors:  Monika Augustyn; Iwon Grys; Michał Kukla
Journal:  Clin Exp Hepatol       Date:  2019-02-20

10.  Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.

Authors:  Yu-ming Chen; Yan Liu; Rui-fen Zhou; Xiao-ling Chen; Cheng Wang; Xu-ying Tan; Li-jun Wang; Rui-dan Zheng; Hong-wei Zhang; Wen-hua Ling; Hui-lian Zhu
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.